• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Can antisense for p53 increase the chemosensitivity of anticancer drugs for lung cancer?

Research Project

Project/Area Number 10671133
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeSingle-year Grants
Section一般
Research Field General surgery
Research InstitutionKeio university

Principal Investigator

KAWAMURA Masafumi  School of Medicine, Keio university Assistant professor, 医学部, 専任講師 (70169770)

Co-Investigator(Kenkyū-buntansha) GIKA Masatoshi  School of Medicine, Keio university Instructor, 医学部, 助手 (60276269)
KUBOTA Tetsuro  School of Medicine, Keio university Assistant professor, 医学部, 専任講師 (00118944)
Project Period (FY) 1998 – 1999
Project Status Completed (Fiscal Year 1999)
Budget Amount *help
¥3,000,000 (Direct Cost: ¥3,000,000)
Fiscal Year 1999: ¥1,300,000 (Direct Cost: ¥1,300,000)
Fiscal Year 1998: ¥1,700,000 (Direct Cost: ¥1,700,000)
Keywordsanticacer drug / chemosensitivity testing / p53 / antisense / cancer suppression gene / p53
Research Abstract

Chemosensitivity testing of anticancer drugs for lung cancer was measured by use of collagen gel droplet embedded drug sensitivity test (CDDST). Corelation between CDDST and clinical response was as below. True positive ratio was 80%. True negative ratio was 100%. Accuracy was 83.3%. Chemosensitivity testings were successfully carried out in 77.2% of 149 resected tumor specimen, 34.1% of 44 bronchoscopic biopsied specimens, 73.6% of 72 disected or biopsied lymph nodes, and 56.4% of 39 aspirated pleural or pericardial effusion. Chemosensitivities of some anticancer drugs for some lung cancercell lines were increased at 42℃ incubation in CDDST.Apoptosis in lung cancer cell lines could be induced at 42℃ in CDDST, if incubation time was prolonged. During this process, increase of p53 m-RNA could not detected. In lung cancer cell line apoptosis might be initiated by activation of p53 protein itself and p53 m-RNA might not relate directly with the initiation of apoptosis. Actually the increase of chemosensitivity of anticancer drugs for lung cancer cell lines were not observed in CDDST with p53 antisense.

Report

(3 results)
  • 1999 Annual Research Report   Final Research Report Summary
  • 1998 Annual Research Report
  • Research Products

    (6 results)

All Other

All Publications (6 results)

  • [Publications] 川村雅文: "抗癌剤感受性試験に基づいた肺癌の化学療法"肺癌の臨床. 1(3). 353-360 (1998)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      1999 Final Research Report Summary
  • [Publications] 川村雅文: "C-N2非小細胞肺癌に対する手術を中心に据えた治療戦略-抗癌剤感受性試験に基づいた術前化学療法の可能性-"第14回肺癌学会ワークショップ記録集. 107-113 (1999)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      1999 Final Research Report Summary
  • [Publications] Masafumi Kawamura, Masatoshi Gika, Koichi Kobayashi: "Chemosensitivity testing for lung cancer"Jpn.J.Lung Cancer Clin.. 1(3). 353-360 (1998)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      1999 Final Research Report Summary
  • [Publications] Masafumi Kawamura, Masayoshi Inoue, Tomohiro Abiko, et al: "Neoadjuvant chemotherapy for cN2 non-small cell lung cancer based on chemosensitivity testing"Controversy on lung cancer treatment-Record of 14th Workshop of Jpn.Lung Cancer Society. 107-113 (1999)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      1999 Final Research Report Summary
  • [Publications] 川村 雅文: "抗癌剤感受性試験に基づいた肺癌の化学療法"肺癌の臨床. 1巻3号. 353-360 (1998)

    • Related Report
      1999 Annual Research Report
  • [Publications] 川村 雅文: "抗癌剤感受性試験に基づいた肺癌の化学療法" 肺癌の臨床. 1巻3号. 353-360 (1998)

    • Related Report
      1998 Annual Research Report

URL: 

Published: 1998-04-01   Modified: 2016-04-21  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi